1 / 20

Hunter Handsfield Terri Warren Victory Murphy Mica Werner

Suppressive Valacyclovir Therapy Soon After Initial Genital Herpes: Clinical Efficacy and Impact on Herpes-Related Quality of Life. Hunter Handsfield Terri Warren Victory Murphy Mica Werner University of Washington and Public Health - Seattle & King County, Seattle, WA

chesna
Download Presentation

Hunter Handsfield Terri Warren Victory Murphy Mica Werner

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Suppressive Valacyclovir Therapy Soon After Initial Genital Herpes: Clinical Efficacy and Impact on Herpes-Related Quality of Life Hunter Handsfield Terri Warren Victory Murphy Mica Werner University of Washington and Public Health - Seattle & King County, Seattle, WA Westover Heights Clinic, Portland, OR

  2. Early Suppressive Therapy for Genital HerpesRationale • Genital herpes is the most prevalent STD in the US • It is the one of greatest concern to sexually active people in the US behind HIV/AIDS • The need for suppressive therapy may be greatest in the first 6-12 months after acquisition when: Outbreaks most common Most viral shedding Most psychological distress • But suppression has been studied in persons with genital herpes a year or more in duration

  3. Early Suppressive Therapy for Genital HerpesPurpose • To determine the efficacy of suppressive treatment with valacyclovir initiated very early in the course of infection • Endpoints: • No. of symptomatic recurrences • Number of patients recurrence free during follow-up • Psychological effect of genital herpes

  4. Study Design • Double-blind, placebo-controlled, randomized trial • Heterosexual men and women • HIV negative by history • Clinical diagnosis of first episode genital herpes • within 60 days prior to enrollment or • within 120 days of first diagnosis and within 60 days of first recurrence

  5. Study Design • Laboratory tests • HSV culture and/or PCR of lesions • Glycoprotein G-based serology for HSV-1 and HSV-2 at enrollment; follow-up serology if initial PCR or culture negative • First episode treatment given for 10 days, if indicated • Then valacyclovir 1 g or placebo QD for 6 months • Recurrences treated with open-label valacyclovir 500 mg bid for 5 days; study drug withheld during this

  6. Study Design • Follow-up • Clinic visits at enrollment, 1 mo, 3 mo, 6 mo and for first suspected recurrent outbreak • Telephone follow-up 2 wk, 2 mo, 4 mo, 5 mo • First recurrence assessed in person, subsequent outbreaks reported by telephone • Herpes-related psychological impact evaluated at baseline, 3 mo and 6 mo

  7. Herpes Related Psychological Impact Assessment (HRPIA)Previously known as Herpes Related Quality of Life • Self-administered, 5-6 min • 20 items, Likert scale (0-3 points) • Minimum score 0, maximum 60 • Subject areas • Self-esteem • Social functioning • Sexual functioning • Personal relationships • Mental health

  8. Herpes Related Psychological Impact Assessment: Sample Items • Herpes affects my self confidence • Herpes is affecting my sex life • I get depressed about having herpes • Herpes makes makes it difficult to plan ahead Very much Quite a bit A little Not at all 0 1 2 3 Higher score is better and rise in score indicates improvement

  9. Data Analysis • Intent to treat (ITT), regardless of diagnostic confirmation • HSV-2 • HSV-1 • HSV, type unknown • HSV not documented • Separate analysis of cases with documented HSV-2 infection N 75 22 2 20

  10. Study Population Valacyclovir N=60 Placebo N=59 • Age, yr, mean + SD • Female, No. (%) • White, No. (%) • New partner 2 mo, No. (%) • HSV diagnosis, No. (%) • HSV-2 • HSV-1 • HSV, type unknown • HSV unconfirmed • HRPIA score, mean + SD • Followed >3 mo, No. (%) 28.5 + 8.9 35 (58) 49 (82) 29 (48) 38 (63) 9 (15) 1 (2) 12 (20) 28.6 + 14.6 44 (73) 29.0 + 8.8 43 (73) 47 (80) 20 (34) 37 (63) 13 (22) 1 (2) 8 (14) 31.2 + 14.8 44 (75)

  11. Recurrent Herpes Outbreaks During Follow-up: ITT Analysis • Outbreak-free, No. (%) • Number of outbreaks Mean + SD Median Range Valacyclovir N=60 Placebo N=59 P 35 (58) 0.7 + 1.0 0 0 - 5 19 (32) 1.6 + 2.0 1 0 - 11 0.006 0.004

  12. 60 Valacyclovir 35 Placebo 50 40 21 30 19 15 20 13 10 7 6 3 0 0 1 2 >3 Recurrent Herpes Outbreaks During Follow-up: ITT Analysis P = 0.004 Percent of Patients Bars display no. of subjects No. of Outbreaks

  13. Recurrent Herpes Outbreaks During Follow-up: Confirmed HSV-2 • Outbreak-free, No. (%) • Number of outbreaks Mean + SD Median Range Valacyclovir N=38 Placebo N=37 P 18 (47) 0.9 + 1.2 1 0 - 5 10 (27) 2.0 + 2.4 1 1 - 11 0.095 0.011

  14. 60 Valacyclovir Placebo 50 18 40 30 12 10 10 20 9 6 10 5 3 0 0 1 2 >3 Recurrent Herpes Outbreaks During Follow-up: Confirmed HSV-2 P = 0.012 Percent of Patients Bars display no. of subjects No. of Outbreaks

  15. Herpes-Related Psychological Impact Assessment: ITT Analysis • 0 3 mo • 0 6 mo Change in HRPIA Score, Mean + SD Valacyclovir Placebo P N N 42 40 14.1 + 12.5 15.5 + 15.0 45 41 10.1 + 8.9 9.7 + 11.1 0.10 0.052

  16. Herpes-Related Psychological Impact Assessment: Confirmed HSV-2 • 0 3 mo • 0 6 mo Change in HRPIA Score, Mean + SD Valacyclovir Placebo N P N 27 25 14.0 + 13.4 14.6 + 16.4 30 28 8.0 + 6.9 6.1 + 9.1 0.039 0.023

  17. Early Suppressive Therapy for Genital HerpesSummary • Suppressive therapy with valacyclovir given within 60-120 days after acquisition of genital herpes is superior to placebo in: • Reducing the # of symptomatic recurrent outbreaks • Ameliorating psychological impact • Suppression may be less effective in preventing symptomatic recurrences in early herpes than in infections >1 year duration

  18. Early Suppressive Therapy for Genital HerpesLimitations • Small trial with limited statistical power • All except the first recurrent outbreaks were self-diagnosed by the patients which may be hypervigilance in newly diagnosed patients rather than actual outbreaks • Recurrence rates have not yet been adjusted for duration of follow-up (I.e. some followed shorter time periods, some longer • No data on subclinical shedding or transmission

  19. Early Suppressive Therapy for Genital HerpesConclusions • Early valacyclovir suppressive therapy is effective in reducing recurrences and improving psychological adjustment • Further study is needed to confirm and extend these pilot results (Planning underway for a multicenter RCT) • The present results support such therapy for selected patients. Counsel patients that their partners may not be protected from transmission even while on suppression.

  20. Early Suppressive Therapy for Genital HerpesAcknowledgments Bob Deeter, formerly of GlaxoSmithKline Jennifer Almekinder, GlaxoSmithKline Jim Phillips, Sage Statistical Solutions Westover Heights Clinic staff Public Health - Seattle & King County STD Clinic staff The patients who served and the providers who referred them

More Related